The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview.
暂无分享,去创建一个
[1] H. Waseem,et al. Probiotic Yeast Saccharomyces: Back to Nature to Improve Human Health , 2022, Journal of fungi.
[2] S. Oveisi,et al. The Effect of the Yeast Probiotic Saccharomyces boulardii on Acute Diarrhea in Children , 2021, Journal of Comprehensive Pediatrics.
[3] N. Adu-Aryee,et al. Antibiotic prescribing and the risk of antibiotic-associated diarrhoea in Korle Bu Teaching Hospital, Ghana: a pilot study. , 2020, Journal of infection in developing countries.
[4] Miguel C. Teixeira,et al. Saccharomyces boulardii: What Makes It Tick as Successful Probiotic? , 2020, Journal of fungi.
[5] G. Su,et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. , 2020, Gastroenterology.
[6] Qiang Xu,et al. Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy , 2020, World journal of clinical cases.
[7] G. Mullin,et al. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. , 2020, Journal of the Academy of Nutrition and Dietetics.
[8] M. Baldeón,et al. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome , 2020, European Journal of Clinical Microbiology & Infectious Diseases.
[9] H. Szajewska,et al. Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update , 2020, Alimentary pharmacology & therapeutics.
[10] T. J. Mansell,et al. Yeasts as probiotics: mechanisms, outcomes, and future potential. , 2020, Fungal genetics and biology : FG & B.
[11] F. F. de Melo,et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection , 2019, World journal of gastroenterology.
[12] Jiafeng Lu,et al. Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases , 2019, Journal of Zhejiang University-SCIENCE B.
[13] A. Helo. Treatment of Irritable Bowel Syndrome with Saccharomyces Cerevisiae: علاج القولون العصبي باستخدام خميرة البيرة , 2019, Journal of medical and pharmaceutical sciences.
[14] W. Wong,et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy , 2019, Front. Microbiol..
[15] S. Soliman,et al. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates , 2019, Pathogens.
[16] D. Pietrella,et al. Probiotic Cell-Free Supernatants Exhibited Anti-Inflammatory and Antioxidant Activity on Human Gut Epithelial Cells and Macrophages Stimulated with LPS , 2018, Evidence-based complementary and alternative medicine : eCAM.
[17] A. Vohra. Benefits of probiotic yeasts in human and animal health , 2017 .
[18] S. Ng,et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. , 2017, Gastroenterology.
[19] W. Kunze,et al. Effects of Saccharomyces cerevisiae or boulardii yeasts on acute stress induced intestinal dysmotility , 2016, World journal of gastroenterology.
[20] Y. Ringel,et al. The Microbiota in Gastrointestinal Pathophysiology: Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis , 2016 .
[21] T. Bozoğlu,et al. Probiotics and Prebiotics , 2016 .
[22] E. Distrutti,et al. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. , 2016, World journal of gastroenterology.
[23] E. Quigley,et al. THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review. , 2015, Arquivos de gastroenterologia.
[24] H. Szajewska,et al. Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea , 2015, Alimentary pharmacology & therapeutics.
[25] A. Swidsinski,et al. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review , 2015, Clinical and experimental gastroenterology.
[26] Liyuan Tao,et al. [A meta-analysis of probiotics for the treatment of irritable bowel syndrome]. , 2015, Zhonghua nei ke za zhi.
[27] S. Vermeersch,et al. Prevalence and management of antibiotic associated diarrhea in general hospitals , 2015, BMC Infectious Diseases.
[28] M. Bull,et al. Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis. , 2015, Integrative medicine.
[29] C. Neut,et al. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[30] A. Kara,et al. Saccharomyces boulardii CNCM I-745 in different clinical conditions , 2014, Expert opinion on biological therapy.
[31] S. Sakarya,et al. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3‐linked sialic acid that decreases Helicobacter pylori adhesion to host cells , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[32] I. Pinchuk,et al. Effect of Helicobacter pylori on gastric epithelial cells. , 2014, World journal of gastroenterology.
[33] M. Akhondi-Meybodi,et al. Study of the Effect of Probiotic Saccharomyces Boulardii on the Treatment of Irritable Bowel Syndrome , 2014 .
[34] G. Demirel,et al. Saccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: a randomized, controlled study , 2013, Acta paediatrica.
[35] E. Oliveira,et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. , 2013, Arquivos de gastroenterologia.
[36] Christy A. Varughese,et al. Antibiotic-Associated Diarrhea , 2013, Journal of pharmacy practice.
[37] M. Łukaszewicz. Saccharomyces cerevisiae var. boulardii – Probiotic Yeast , 2012 .
[38] R. Korpela,et al. Probiotics and irritable bowel syndrome , 2012, Microbial ecology in health and disease.
[39] C. Pothoulakis,et al. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders , 2012, Therapeutic advances in gastroenterology.
[40] C. Choi,et al. A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces boulardii in Irritable Bowel Syndrome: Effect on Quality of Life , 2011, Journal of clinical gastroenterology.
[41] L. Mcfarland. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. , 2010, World journal of gastroenterology.
[42] C. Pothoulakis. Review article: anti‐inflammatory mechanisms of action of Saccharomyces boulardii , 2009, Alimentary pharmacology & therapeutics.
[43] S. Alam,et al. Antibiotic associated diarrhea in children. , 2009, Indian pediatrics.
[44] M. Sajin,et al. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children , 2009, Acta paediatrica.
[45] L. Mcfarland. Antibiotic-associated diarrhea: epidemiology, trends and treatment. , 2008, Future microbiology.
[46] J. Heimbach,et al. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] P. Rampal,et al. Review article: yeast as probiotics –Saccharomyces boulardii , 2007, Alimentary pharmacology & therapeutics.
[48] A. Dursun,et al. Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study , 2007, Helicobacter.
[49] B. Flourié,et al. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[50] E. Şahin,et al. Effect of Saccharomyces boulardii in Children with Acute Gastroenteritis and Its Relationship to the Immune Response , 2007, The Journal of international medical research.
[51] D. Forman,et al. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study , 2006, Gut.
[52] B. Beşirbellioğlu,et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. , 2006, Medical science monitor : international medical journal of experimental and clinical research.
[53] M. Heitkemper,et al. Abdominal Pain Impacts Quality of Life in Women with Irritable Bowel Syndrome , 2006, The American Journal of Gastroenterology.
[54] M. Gotteland,et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori , 2005, Acta paediatrica.
[55] H. Szajewska,et al. Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea in children: a randomized double‐blind placebo‐controlled trial , 2005, Alimentary pharmacology & therapeutics.
[56] X. Badia,et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype , 2003, European journal of gastroenterology & hepatology.
[57] A. Gasbarrini,et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study , 2002, American Journal of Gastroenterology.
[58] P. Periti,et al. Preclinical and Clinical Pharmacology of Biotherapeutic Agents: Saccharomyces boulardii , 2001, Journal of chemotherapy.
[59] J. Nicoli,et al. Antagonistic effect of Lactobacillus acidophilus, Saccharomyces boulardii and Escherichia coli combinations against experimental infections with Shigella flexneri and Salmonella enteritidis subsp. typhimurium in gnotobiotic mice , 2000, Journal of applied microbiology.
[60] L. Mcfarland,et al. Epidemiology, Risk Factors and Treatments for Antibiotic-Associated Diarrhea , 1998, Digestive Diseases.
[61] C. Surawicz,et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. , 1995, The American journal of gastroenterology.
[62] C. Surawicz,et al. Recovery and Elimination of the Biotherapeutic Agent, Saccharomyces boulardii, in Healthy Human Volunteers , 1993, Pharmaceutical Research.
[63] J. Hotz. [Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study]. , 1990, Zeitschrift fur Gastroenterologie.
[64] R. Ducluzeau,et al. [Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice]. , 1982, Annales de microbiologie.
[65] D. Graham,et al. Current and Future Treatment of Helicobacter pylori Infections. , 2019, Advances in experimental medicine and biology.
[66] L. Mcfarland. Common Organisms and Probiotics: Saccharomyces boulardii , 2017 .
[67] M. Vukmirovic,et al. Beneficial properties of probiotic yeast Saccharomyces boulardii , 2016 .
[68] R. Krishnamurthy,et al. SACCHAROMYCES BOULARDII-A PROBIOTIC OF CHOICE , 2013 .
[69] D. Bunout,et al. [Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment]. , 2008, Revista medica de Chile.
[70] Copyright © 1997, American Society for Microbiology , 1996 .
[71] [Controlled double blind clinical trials of lyophilized Ultra-Levure. Multiple-center study by 25 physicians of 388 cases]. , 1976, Medecine & chirurgie digestives.
[72] G. Barbara,et al. The Immune System in Irritable Bowel Syndrome , 2011, Journal of neurogastroenterology and motility.